Why choose biosimilars now and in the future?

Biosimilars facilitate patient access, provide more affordable treatment options and encourage innovation1,2

The many advantages of biosimilars:

Lower cost

The development of biosimilars can create lower patient costs for treatment, which can lead to:

  • Increased uptake of best-value biologics1,2
  • Reinvestment of cost savings in the development of new and innovative therapies1
  • Improved patient care1 

Increased choice and access

Biosimilars can offer increased access to biological products for patients. This can lead to:

  • Additional treatment choices for patients and HCPs1,2
  • Increased access to treatment options not previously available1

Encouraging innovation 

The development of biosimilars can create a more progressive, competitive environment, encouraging investment in the development of new biologic products. This can lead to:

  • Innovation among reference product manufacturers1 
  • Increased patient access to biosimilars and the most modern medicines1,2
     
  • Increased uptake of best-value biologics1,2
  • Reinvestment of cost savings in the development of new and innovative therapies1
  • Improved patient care1


Why choose our biosimilars? Learn here

References
1. IMS Institute 2016. Delivering on the potential of biosimilar medicines. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf (Accessed February 2019). 2. IMS Health 2016. The impact of biosimilar competition. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2016/08/IMS-Impact-of-Biosimilar-Competition-2016.pdf (Accessed February 2019).